<DOC>
	<DOCNO>NCT02058095</DOCNO>
	<brief_summary>To determine effect 12 week chronic PDEV inhibition Tadalafil versus placebo basal cardiorenal humoral function integrate cardiorenal humoral response acute sodium load subject preclinical Diastolic dysfunction ( PDD ) renal ( kidney ) dysfunction</brief_summary>
	<brief_title>Study Determine How Cialis Effects Renal Function Response Volume Expansion Preclinical Diastolic Cardiomyopathy ( Aim3 )</brief_title>
	<detailed_description>At consent visit blood draw do also 6 minute walk do determine eligibility physical exam along vital sign , height weight do . Twenty-four hour urine collection obtain one day prior active study day . Prior initiation study , subject stabilize least one week add salt diet ( 120 milliequivalent sodium/salt per day ( mEq Na/day ) maintain throughout study period . Subjects admit Clinical Research Unit ( CRU ) even active study day . They able order no-added salt meal anything eat midnight last renal clearance blood draw next day . Bladder scan carry assess urine retention . On active study day , subject take medication upon awaken , however , diabetic hold diabetic medication last renal clearance test able order regular diet meal take diabetic medication . Subjects ask drink 5ml/Kg ( milliliter per kilogram body weight ) water insure sufficient urinary flow . A priming dose ( calculated accord body size ) Iothalamate , measure glomerular filtration rate ( GFR ) para-amino-hippurate ( PAH ) measure effective renal plasma flow ( ERPF ) infuse , follow constant rate IV sustain dose ( calculated accord estimate kidney function ) Iothalamate PAH . The subject ask empty bladder spontaneously every thirty minute . Throughout study , end 30-minute clearance period , subject ask drink amount water equivalent sum blood loss urinary flow . After equilibration period 45 minute , 30-minute baseline renal clearance carry . Blood pressure measure 20-minute interval use automatic blood pressure cuff , heart rate continuously monitor electrocardiography . Echocardiography perform baseline clearance determine leave atrial ( LA ) Left Ventricular ( LV ) volumes systolic diastolic function . After baseline clearance acute saline load administer ( normal saline 0.9 % 0.25 ml/kg/min 1 hour ) . During 1 hour saline load , one 30-minute clearance ( outline ) repeat subject supine position second 30-minute clearance repeat subject sit head bed . As , blood sample collect midway clearance urine sample obtain every 30 minute . Echocardiography repeat immediately end saline infusion . At completion baseline renal clearance period response acute sodium load , subject randomize Tadalafil placebo . Subjects randomize 2:1 fashion . All subject take oral Tadalafil ( 5 mg ) placebo day . The blood pressure check prior administering drug.Thereafter , blood pressure heart rate continue monitor next 4 hour . If first dose study drug patient 's systolic blood pressure &lt; 85 mmHg systolic symptom hypotension e.g . lightheadedness , dizziness , feel faint , blur vision , study drug stop however subject continue study . After 2 hour blood pressure &gt; 95 systolic give 1 ( 5 mg ) Tadalafil placebo monitor blood pressure 2 hour . If blood pressure &gt; 95 dismiss subject 2 ( 5 mg ) tab tadalafil placebo . If blood pressure 90 - 95 mmHg systolic , dismiss 1 ( 5 mg ) tab Tadalafil placebo . Patients dismiss . Subjects also access 24-hour phone number question develop side effect . Subjects return one week ( + - 4 day ) electrolyte check . They also receive weekly phone call review status . At 2 week ( ± 5 day ) dismissal blood pressure &gt; 100 add 1 ( 5 mg ) tab Tadalafil placebo make total 3 ( 5mg ) tab Tadalafil placebo . At 4 week ( ± 5 day ) blood pressure &gt; 100 add 1 ( 5 mg ) tab make total 4 ( 5 mg ) Tadalafil placebo . After six week ( + - 5 day ) , subject repeat blood draw safety lab ( total blood count electrolyte ) . For patient live 25 mile away try arrange visit patient 's local physician . At end twelve-week study period ( + - 8 day ) , subject admit Clinical Research Unit afternoon prior renal clearance study . Echocardiography , renal clearance , humoral determination acute saline load perform manner baseline study . Subjects also perform 24-hour urine collection day prior return visit determination sodium excretion creatinine clearance . Subjects dismiss renal clearance study .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>A total 39 patient PDD define ejection fraction great 50 % , clinical sign symptom congestive heart failure , minimal distance 6minute walk equal &gt; 450 meter recruit calculated creatinine clearance equal le 90 ml/min great 30 ml/min , use ( MDRDmeasurement renal dysfunction , formula ) assess within past 36 month . If subject able walk 450 meter due pain hip knee fatigue shortness breath still qualify protocol . • Current anticipate future need nitrate therapy Systolic blood pressure &lt; 90 mmHg &gt; 180 mm Hg Diastolic blood pressure &lt; 40 mmHg &gt; 100 mmHg Patients take alpha antagonist cytochrome P450 3A4 inhibitor ( ketoconazole , itraconazole , erythromycin , saquinavir , cimetidine serum proteases inhibitor HIV ) take medication duration study . Patients take follow selective alpha blocker unable stop duration study ; Alfuzosin Prazosin Doxazosin Tamsulosin Terazosin Silodosin Patients retinitis pigmentosa , previous diagnosis nonischemic optic neuropathy , untreated proliferative retinopathy unexplained visual disturbance Patients sickle cell anemia , multiple myeloma , leukemia penile deformity place risk priapism ( angulation , cavernosal fibrosis Peyronie 's disease ) Patients allergy iodine . Patients PDEV inhibition pulmonary hypertension Patients PDEV inhibition erectile dysfunction willing stop medication duration study Valve disease ( &gt; moderate aortic mitral stenosis ; &gt; moderate aortic mitral regurgitation ) Obstructive Hypertrophic cardiomyopathy Infiltrative inflammatory myocardial disease ( amyloid , sarcoid ) Pericardial disease Have experience myocardial infarction unstable angina , undergone percutaneous transluminal coronary angiography ( PTCA ) coronary artery bypass grafting ( CABG ) within 60 day prior consent , require either PTCA CABG time consent Severe congenital heart disease Sustained ventricular tachycardia ventricular fibrillation within 14 day screen Second third degree heart block without permanent cardiac pacemaker Stroke within 3 month screen evidence significantly compromised Central Nervous System ( CNS ) perfusion Hemoglobin &lt; 9 g/dL Patients severe liver disease ( AST &gt; 3x normal , alkaline phosphatase bilirubin &gt; 2x normal ) Serum sodium &lt; 125 mEq/dL &gt; 150 mEq/dL Serum potassium &lt; 3.2 mEq/dL &gt; 5.9 mEq/dL Prior diagnosis intrinsic renal disease include renal artery stenosis &gt; 50 % Peritoneal hemodialysis within 90 day anticipation dialysis ultrafiltration form require study period Less 21 year age Pregnant nursing woman . Women child bear potential negative pregnancy test study entry use effective contraception Noncardiac condition limit life expectancy le one year , per physician judgment Other acute chronic medical condition laboratory abnormality may increase risk associate study participation may interfere interpretation data Received investigational drug within 1 month prior dose In opinion investigator unlikely comply study protocol unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>